EUVIMEDDescubrir EUVIMED
Open access · CC BY 4.0

Molecular Hybridization of Clinically Relevant P2X7 Antagonists

Nicholas B Lynch, Charleigh T A Agius, André D J McKenzie, Jessica O'Driscoll, Angus Tolmie, Taylor R Garrett, Eryn Werry iD, Michael Kassiou iD

ChemMedChem · 2026-07-14 · 21 (13)

DOI: 10.1002/cmdc.70371 ↗

At a glance

Journal article in ChemMedChem, published online on 2026-07-08. Written by Nicholas B Lynch and 7 co-authors. Institution: School of Chemistry, Faculty of Science, The University of Sydney, Sydney, New South Wales, Australia. Major MEDLINE topics: Receptors, Purinergic P2X7, Purinergic P2X Receptor Antagonists. 46 references. The full text is freely available (open access, CC BY 4.0). Funded by: Australian Government Research Training Program..

ResumenSubjectsDatos bibliográficosCiteRelated studies

Abstract (original language)

The P2X7 receptor plays a pivotal role in the development of neurodegenerative disease states, yet no therapies targeting this receptor have reached the market to date. This work utilized a hybridization approach to combine clinically relevant antagonists AZD‐9056 and JNJ‐54175446 to discover new P2X7 antagonists. Here, we report the synthesis and in vitro and in silico evaluation of a library of 22 compounds to explore new chemical space around these clinically validated molecules. This study emphasizes the value of molecular hybridization in drug discovery and provides the basis for future P2X7 receptor antagonist development.

Subjects

MeSH terms (MEDLINE)

Receptors, Purinergic P2X7Purinergic P2X Receptor AntagonistsHumansStructure-Activity RelationshipMolecular Structure

Author keywords

P2X receptorP2X7P2X7R antagonistcentral nervous systemneurodegenerative disease

Substances

Receptors, Purinergic P2X7Purinergic P2X Receptor Antagonists

Authors and institutions

  • School of Chemistry, Faculty of Science, The University of Sydney, Sydney, New South Wales, Australia.
  • Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.

ORCID profiles: Eryn Werry, Michael Kassiou

Funding

  • Australian Government Research Training Program.

Cite

APA

Lynch, N. B., Agius, C. T. A., McKenzie, A. D. J., O'Driscoll, J., Tolmie, A., Garrett, T. R., Werry, E., & Kassiou, M. (2026). Molecular Hybridization of Clinically Relevant P2X7 Antagonists. ChemMedChem, 21(13). https://doi.org/10.1002/cmdc.70371

Vancouver

Lynch NB, Agius CTA, McKenzie ADJ, O'Driscoll J, Tolmie A, Garrett TR, et al. Molecular Hybridization of Clinically Relevant P2X7 Antagonists. ChemMedChem. 2026;21(13). doi:10.1002/cmdc.70371

BibTeX
@article{Lynch2026,
  author = {Lynch, Nicholas B and Agius, Charleigh T A and McKenzie, André D J and O'Driscoll, Jessica and Tolmie, Angus and Garrett, Taylor R and Werry, Eryn and Kassiou, Michael},
  title = {Molecular Hybridization of Clinically Relevant P2X7 Antagonists},
  journal = {ChemMedChem},
  year = {2026},
  volume = {21},
  number = {13},
  doi = {10.1002/cmdc.70371}
}
Start for free →